Intro Pullout Text Widget

RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.806
Citescore: 7.1
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team

Current Issue

New Editor-in-Chief: Professor Gerd Burmester

BMJ and EULAR are delighted to announce that Professor Gerd Burmester has been appointed as the new Editor-in-Chief for RMD Open.

Professor Burmester was the Director of the Department of Rheumatology and Clinical Immunology at the Charité Universitätsmedizin Berlin until very recently and is now a Senior Professor at this institution. He is a former President of EULAR. Since 2017 he has been President of the Board of Trustees of the FOREUM Foundation for Research in Rheumatology.

Professor Burmester has been an active supporter of RMD Open since its inception and we're excited that he has agreed to take the journal forward into its next stage of development.

Intro Pullout Text Widget

RMD Open

New Editor-in-Chief: Professor Gerd Burmester

Latest Articles

Original research:

Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force

Vasculitis:

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis

Infections:

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry

Lupus:

Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis

Miscellaneous:

EULAR points to consider for including the perspective of young patients with inflammatory arthritis into patient-reported outcomes measures

Why submit to RMD Open?

RMD Open

Most Read Articles

Infections:

Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey

Rheumatoid arthritis:

After 25 years of drug development, do we know JAK?

Psoriatic arthritis:

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes

Miscellaneous:

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

Infections:

Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up

COVID-19 Content

LETTER:

Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

INFECTIONS:

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses

INFECTIONS:

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)

AUTOINFLAMMATORY DISORDERS:

COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases

INFECTIONS:

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?